$1 Billion AI Revenue Secured, ChronoScale Divests Bionics Unit
CHRN has more than doubled off its 52-week low of $3.5.
Summary
ChronoScale announced new customer agreements that boost its total contracted run-rate revenue to $1 billion by Q3 2027. This significant expansion follows the company's recent 10-K filing, which reported a $50.3 million net loss. Additionally, ChronoScale completed the sale of its Ekso Bionics business unit, a move anticipated by a September 16th 8-K filing that amended a loan agreement to facilitate the divestiture. The $1 billion contracted revenue dramatically alters the company's financial outlook and validates its AI infrastructure strategy. Divesting Ekso Bionics allows ChronoScale to fully concentrate resources on its core, high-growth AI compute platform.
At the time of this announcement, CHRN was trading at $20.29 on NASDAQ in the Technology sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $3.50 to $30.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.